SYK and arthritic joint disease: To this end, we used potent and selective small molecule inhibitors of pan-JAKs (tofacitinib) and SYK (PRT062607) either in combination or alone, which were tested, for the first time, in a destructive and non-remitting arthritis murine model [20, 21].